Bridgebio Pharma share price today
(NASDAQ: BBIO)

Name: Bridgebio Pharma Share Price Today (NASDAQ: BBIO) - Bridgebio Pharma Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Bridgebio Pharma share price is $37.09 & ₹3,207.91 as on 24 Jan 2025, 2.30 'hrs' IST

$37.09

▲

1.25

(3.49%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Bridgebio Pharma share price in Dollar and Rupees. Guide to invest in Bridgebio Pharma stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Bridgebio Pharma, along with analyst recommendations, forecasts, and comprehensive financials.

Bridgebio Pharma share price movements

Today's Low: $35.32
Today's High: $37.46
$37.09
4.77%
Downside
Day's Volatility :5.71%
Upside
0.99%
52 Weeks Low: $21.62
52 Weeks High: $41.04
$37.09
41.71%
Downside
52 Weeks Volatility :47.32%
Upside
9.62%

Bridgebio Pharma Returns

Period	Bridgebio Pharma Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	50.34%	-5.5%	0.0%
6 Months	32.5%	-4.3%	0.0%
1 Year	-0.64%	1.6%	0.0%
3 Years	249.66%	9.8%	-11.0%

Bridgebio Pharma Key Statistics

in dollars & INR

Previous Close	$35.84
Open	$35.54
Today's High	$37.46
Today's Low	$35.32
Market Capitalization	$6.8B
Today's Volume	$1.8M
52 Week High	$41.04
52 Week Low	$21.62
Revenue TTM	$217.8M
EBITDA	$-509.9M
Earnings Per Share (EPS)	$-2.58
Profit Margin	-201.53%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-1789.67%

How to invest in Bridgebio Pharma Stock (BBIO) from India?

It is very easy for Indian residents to invest directly in Bridgebio Pharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Bridgebio Pharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Bridgebio Pharma or BBIO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Bridgebio Pharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Bridgebio Pharma shares which would translate to 0.023 fractional shares of Bridgebio Pharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Bridgebio Pharma, in just a few clicks!

Returns in Bridgebio Pharma for Indian investors in Rupees

Investment Value

₹1,00,000

Bridgebio Pharma investment value today

Current value as on today

₹1,06,882

Returns

₹6,882

(+6.88%)

Returns from Bridgebio Pharma Stock

₹2,828 (+2.83%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Bridgebio Pharma

41%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Bridgebio Pharma on INDmoney from India has grown in the last 30 days as on Jan 24, 2025. 41% more investors are searching Bridgebio Pharma in the last 30 days versus the previous period.

Global Institutional Holdings in Bridgebio Pharma

Kohlberg Kravis Roberts & Co LP
13.37%
Viking Global Investors LP
13.29%
Vanguard Group Inc
7.51%
BlackRock Inc
6.81%
Aisling Capital Management LP
3.21%
State Street Corp
3.16%

Analyst Recommendation on Bridgebio Pharma

Buy

85%Buy

15%Hold

0%Sell

Based on 20 Wall street analysts offering stock ratings for Bridgebio Pharma(by analysts ranked 0 to 5 stars)

Based on 20 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Bridgebio Pharma

What analysts predicted

Upside of 33.26%

Target:

$49.43

Current:

$37.09

Insights on Bridgebio Pharma

Price Movement
In the last 1 month, BBIO stock has moved up by 29.1%
Increasing Revenue
Revenue is up for the last 2 quarters, 2.16M → 2.73M (in $), with an average increase of 20.6% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -35.21M → -162.04M (in $), with an average decrease of 114.6% per quarter
BBIO vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 40.5% return, outperforming this stock by 44.0%
Price to Sales
ForBBIO every $1 of sales, investors are willing to pay $30.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.1 for every $1 of sales.

Bridgebio Pharma Technicals Summary

Sell

Neutral

Buy

Bridgebio Pharma is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Bridgebio Pharma Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Bridgebio Pharma Inc	25.62%	32.5%	-0.64%	249.66%	2.99%
Biontech Se	0.91%	34.01%	18.85%	-26.4%	246.9%
Regeneron Pharmaceuticals, Inc.	-4.82%	-36.95%	-28.33%	12.74%	100.35%
Vertex Pharmaceuticals Incorporated	4.86%	-13.58%	-0.46%	88.45%	88.24%
Alnylam Pharmaceuticals, Inc.	9.57%	13.5%	44.91%	103.56%	127.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Bridgebio Pharma Inc	NA	NA	NA	-2.39	-17.9	-0.49	NA	-6.51
Biontech Se	160.8	NA	0.04	-3.33	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.02	17.02	1.05	44.99	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Bridgebio Pharma Inc	Buy	$6.8B	2.99%	NA	-201.53%
Biontech Se	Buy	$28.1B	246.9%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.6B	100.35%	17.02	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$110.2B	88.24%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	127.75%	NA	-15.86%

Bridgebio Pharma Dividend announcements

Bridgebio Pharma Earnings
Bridgebio Pharma’s price-to-earnings ratio stands at None
Read More

About Bridgebio Pharma

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Organization	Bridgebio Pharma
Employees	550
CEO	Dr. Neil Kumar Ph.D.
Industry	Health Technology

Management People of Bridgebio Pharma

Name	Title
Dr. Neil Kumar Ph.D.	Co-Founder, CEO & Director
Dr. Charles J. Homcy M.D.	Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
Dr. Frank P. McCormick Ph.D.	Co-Founder, Chairman of Oncology & Director
Dr. Brian C. Stephenson C.F.A., Ph.D.	CFO & Secretary
Dr. Richard H. Scheller Ph.D.	Chairman of Research & Development
Dr. Thomas Trimarchi Ph.D.	President & COO
Dr. Uma Sinha Ph.D.	Chief Scientific Officer
Grace Rauh	Vice President of Communications
Mr. Eli M. Wallace Ph.D.	Chief Scientific Officer of Oncology
Dr. Eric Michael David J.D., M.D., Ph.D.	Chief Executive Officer of Gene Therapy

Important FAQs about investing in Bridgebio Pharma (BBIO) from India :

What is Bridgebio Pharma share price today?

Bridgebio Pharma share price today stands at $37.09, Open: $35.54 ; Previous Close: $35.84 ; High: $37.46 ; Low: $35.32 ; 52 Week High: $41.04 ; 52 Week Low: $21.62. The stock opens at $35.54, after a previous close of $35.84. The stock reached a daily high of $37.46 and a low of $35.32, with a 52-week high of $41.04 and a 52-week low of $21.62.

Can Indians buy Bridgebio Pharma shares?

Yes, Indians can invest in the Bridgebio Pharma (BBIO) from India.

With INDmoney, you can buy Bridgebio Pharma at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Bridgebio Pharma at zero transaction cost.

How can I buy Bridgebio Pharma shares from India?

It is very easy to buy Bridgebio Pharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Bridgebio Pharma be purchased?

Yes, you can buy fractional shares of Bridgebio Pharma with INDmoney app.

What are the documents required to start investing in Bridgebio Pharma stocks?

To start investing in Bridgebio Pharma, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.